Clinical trial · Interventional
A Study of HR19024 in Subjects With Advanced Solid Tumor
An Open-label Phase 1a Study of the Safety and Tolerability of HR19024 Injection in Subjects With Advanced Solid Tumor
NCT05463432CI-TRIAL-00087432completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the safety，tolerability，pharmacokinetic characteristics and preliminary efficacy of HR19024 injection in the treatment of advanced solid tumor
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HR19024 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HR19024
- description
- Part 1: Dose escalation of HR19024 montherapy for advanced solid tumor Part 2：PK expansion of HR19024 montherapy for advanced solid tumor Part 3: Efficacy expansion of HR19024 montherapy for advanced solid tumor
- interventionNames
- Drug: HR19024
Primary outcomes (1)
- measure
- Maximum tolerated dose (MTD) of HR19024
- timeFrame
- 21-day cycle (tri-weekly)
Secondary outcomes (4)
- measure
- Response rate (RR)
- timeFrame
- up to 6 months following the date the last patient was randomized
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. ECOG performance status 0 or 1 2. Histologically confirmed advanced solid tumor 3. Life expectancy of greater than or equal to (\>=) 12 weeks 4. At least one measurable lesion is present according to the efficacy evaluation criteria for solid tumors (RECIST 1.1) 5. Able and willing to provide a written informed consent Exclusion Criteria: 1. Subjects with unresolved toxicity （\> CTCAE G1）of prior therapy at the time of enrolment 2. Subjects who had received anti-tumor treatments such as surgery, chemotherapy, radiotherapy recently
References
Publications (0)
Data not yet available
No reference posted for this study.